Clinical Report: Investigating Adverse Cutaneous Reactions Related to Medications

Overview

This report highlights the increasing recognition of adverse cutaneous reactions associated with various medications, particularly immune checkpoint inhibitors (ICIs) and Janus Kinase inhibitors (JAKi). Key findings include the identification of specific autoantigens in bullous pemphigoid and the need for improved risk stratification in severe cutaneous adverse reactions.

Background

Adverse cutaneous reactions to medications can significantly impact patient quality of life and treatment adherence. With the rise of immunotherapy and targeted therapies, understanding these reactions is crucial for optimizing patient management. This report synthesizes recent findings on cutaneous immune-related adverse events and their implications for clinical practice.

Data Highlights

No numerical data available in the source material.

Key Findings

• Dupilumab has shown efficacy in treating immune checkpoint inhibitor-induced bullous pemphigoid.
• SCORTEN parameters may need recalibration for better mortality risk stratification in Stevens-Johnson syndrome and toxic epidermal necrolysis.
• JAKi are associated with increased risk of infections, including herpes and pneumonia.
• Topical ruxolitinib has a favorable safety profile but may lead to localized infections.
• Topical steroid abuse can lead to significant adverse effects, including iatrogenic Cushing syndrome.

Clinical Implications

Healthcare providers should maintain vigilance regarding the potential for severe cutaneous adverse reactions in patients receiving immunotherapy and targeted therapies. Early recognition and appropriate management strategies are essential to mitigate risks and improve patient outcomes.

Conclusion

Adverse cutaneous reactions related to medications are a growing concern in clinical practice, necessitating ongoing research and improved management strategies to enhance patient safety and treatment efficacy.

Related Resources & Content

1. Dermatology and Therapy, 2026 -- Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis
2. Blood Cancer Journal, 2026 -- Skin-related adverse effects associated with CAR T-cell therapy in blood cancers
3. Drugs - Real World Outcomes, 2019 -- Analysis of Severe Skin Reactions Linked to Allopurinol: Insights from a Spontaneous Reporting System in Southern Italy
4. National Comprehensive, 2025 -- Guidelines for the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 2025 Supplement
5. The ASCO Post — LETTER TO THE EDITOR: Adjuvant Therapy in Cutaneous Melanoma: The Need for a New Approach
6. NCCN Management of Immunotherapy-Related Toxicities
7. Bullous pemphigoid and mucous membrane pemphigoid humoral responses
8. Guidelines for the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 2025 Supplement - PubMed